Latest Insider Transactions at Aprea Therapeutics, Inc. (APRE)
This section provides a real-time view of insider transactions for Aprea Therapeutics, Inc. (APRE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aprea Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aprea Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 25
2021
|
Scott M Coiante SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,500
+43.63%
|
-
|
|
Feb 25
2021
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
165,500
+41.66%
|
-
|
|
Feb 25
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+50.0%
|
-
|
|
Feb 25
2021
|
Gregory S. Wessels SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 25
2021
|
Eyal C. Attar SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+45.49%
|
-
|
|
Dec 28
2020
|
Redmile Group, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-11.06%
|
$2,500,000
$5.69 P/Share
|
|
Oct 05
2020
|
5 Am Ventures Iv, L.P. |
SELL
Open market or private sale
|
Indirect |
175,000
-55.82%
|
$4,375,000
$25.3 P/Share
|
|
Oct 07
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+14.99%
|
$6,000,000
$15.0 P/Share
|
|
Oct 07
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,868,718
+50.0%
|
-
|